Jim Simons Minerva Neurosciences, Inc. Transaction History

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Minerva Neurosciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 128,100 shares of NERV stock, worth $261,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares

128,100

Previous 157,200 18.51%

Holding current value

$261,324

Previous $419,000 32.22%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$2.1 - $2.7 $61,110 - $78,570	-29,100 Reduced 18.51%	128,100 $284,000
Q3 2024 Nov 13, 2024	SELL	$2.55 - $3.4 $26,774 - $35,700	-10,500 Reduced 6.26%	157,200 $419,000
Q2 2024 Aug 09, 2024	SELL	$2.33 - $3.65 $23,451 - $36,737	-10,065 Reduced 5.66%	167,700 $534,000
Q1 2024 May 13, 2024	BUY	$2.5 - $12.47 $176,412 - $879,945	70,565 Added 65.83%	177,765 $459,000
Q4 2023 Feb 13, 2024	BUY	$3.96 - $7.85 $51,480 - $102,050	13,000 Added 13.8%	107,200 $659,000
Q3 2023 Nov 14, 2023	SELL	$6.9 - $13.05 $28,290 - $53,505	-4,100 Reduced 4.17%	94,200 $650,000
Q2 2023 Aug 11, 2023	SELL	$1.62 - $10.19 $20,250 - $127,375	-12,500 Reduced 11.28%	98,300 $898,000
Q1 2023 May 12, 2023	BUY	$1.51 - $3.09 $755 - $1,545	500 Added 0.45%	110,800 $177,000
Q4 2022 Feb 13, 2023	BUY	$1.43 - $13.43 $12,155 - $114,155	8,500 Added 8.35%	110,300 $175,000
Q3 2022 Nov 14, 2022	BUY	$2.53 - $13.17 $167,458 - $871,709	66,189 Added 185.87%	101,800 $940,000
Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.68 $96,149 - $273,492	35,611 New	35,611 $118,000

Others Institutions Holding NERV

# of Institutions

Shares Held

2.07M

Call Options Held

Put Options Held

View Full List

About Minerva Neurosciences, Inc.

Ticker NERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,340,190
Market Cap $10.9M
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...

More about NERV

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account